TB bacteria mutate during airborne transmission, revealing drug-resistance target

When someone with tuberculosis coughs, they release a cloud of microscopic droplets into the air. As these droplets evaporate, they shrink into particles so small they can drift through a room and lodge deep in another person's lungs. The bacteria survive this journey—a feat nearly as contagious as measles. But researchers at Weill Cornell Medicine have now discovered that survival during this airborne passage comes at a cost to the bacteria themselves, one that paradoxically makes them more dangerous: they mutate in ways that render them resistant to the drugs meant to kill them.

Tuberculosis kills roughly 1.2 million people each year and infects nearly 11 million more globally. It remains one of the world's most lethal infectious diseases, yet the mechanics of how it spreads from person to person—the actual moment when bacteria transform from one body to another—has been largely overlooked in research. A study published in Nature Microbiology reveals that this transmission stage is not simply a passive transfer but an active evolutionary crucible where the pathogen adapts and changes.

The Weill Cornell team recreated the conditions of airborne transmission in the laboratory, watching what happens to Mycobacterium tuberculosis as it dries. The bacteria face severe stress during this process. Drying causes oxidative damage that breaks their DNA. In response, the bacteria activate a repair mechanism—a genetic program designed to fix the damage and allow survival once moisture returns. This is where the trouble begins. The very act of repairing DNA damage while under extreme stress generates mutations. Some of these mutations confer resistance to rifampin, one of the most important antibiotics in tuberculosis treatment.

Rifampin is the backbone of modern TB therapy, allowing doctors to cure the disease in four to six months rather than years. But rifampin-resistant strains are spreading. When resistance emerges, patients face a grim choice: take drugs that are far more toxic, far more expensive, and require treatment lasting many months or even years. The researchers identified a specific gene called Mfd that orchestrates this DNA repair response. When they silenced Mfd in laboratory experiments, drug-resistant tuberculosis bacteria could not survive the drying process as effectively. The finding suggested a new angle of attack: not targeting the bacteria directly, but disabling the survival mechanism it activates during transmission.

To test whether this laboratory insight held true in the real world, the team analyzed more than 50,000 tuberculosis genomes collected from patients across the globe. They found that bacterial strains carrying mutations in Mfd were significantly less likely to carry the most common rifampin-resistance mutation. This pattern supported the laboratory evidence: Mfd helps drug-resistant TB strains survive the airborne journey between people. The implication is striking. The same genetic machinery that allows tuberculosis to spread efficiently also creates the conditions for resistance to emerge. Understanding this link opens a new therapeutic avenue.

Dr. Kyu Rhee, the senior author, noted that tuberculosis has evolved over millennia to spread from person to person with remarkable efficiency. The bacteria have developed specific mechanisms to withstand the stresses of airborne transmission. But evolution works both ways. If those mechanisms can be blocked—if Mfd can be inhibited during the transmission stage—the bacteria become more vulnerable. The bacteria cannot both survive drying and resist the drug. This is not a cure, but it is a pressure point.

The researchers emphasize that therapies targeting the transmission stage could work alongside existing treatments, not replace them. The goal is to slow the emergence and spread of drug-resistant strains by making it harder for resistant bacteria to complete their journey from one person to another. For a disease that kills more than three people every minute, even incremental progress in understanding how it spreads and evolves offers a foothold for intervention. The next phase is moving from laboratory findings to actual drug development—a process that typically takes years. But the target is now visible.